1027594-22-4Relevant academic research and scientific papers
Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines
Ife, Robert J.,Brown, Thomas H.,Blurton, Peter,Keeling, David J.,Leach, Colin A.,et al.
, p. 2763 - 2773 (2007/10/03)
Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation.Compounds bearing a tertiary 4-(arylamino)substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines.We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C5, analogous to the 3-acylquinolines.Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with Ki values down to 12 nM.Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously.However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.
Substituted thienopyrimidine derivatives, their preparation, pharmaceutical compositions and medical use
-
, (2008/06/13)
Compounds of structure in which R1 and R2 are the same, or different and are each hydrogen, C1 4alkyl, -(CH2)nAr in which n is 0 to 4 and Ar is an optionally substituted phenyl group, or R1 and R2 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms, and R3 and R4 are the same or different and are each hydrogen, C1 4alkyl, (CH2)nAr1 in which n is O to 4 and Ar1 is an optionally substituted phenyl group, or R3 and R4 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms, R5 is hydrogen, C1 4alkyl, C1 4alkoxy or COC1 4alkyl; n is 1 or 2; A is -SCH=CH-, -CH=CHS- or =CHSCH=, and the dotted line indicates the presence of a double bond when A is -SCH=CH- or -CH=CHS-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as anti-ulcer agents.
